TY - JOUR
T1 - Venous thromboembolic disease
T2 - Clinical Practice Guidelines in Oncology
AU - Streiff, Michael B.
AU - Bockenstedt, Paula L.
AU - Cataland, Spero R.
AU - Chesney, Carolyn
AU - Eby, Charles
AU - Fanikos, John
AU - Fogerty, Annemarie E.
AU - Gao, Shuwei
AU - Goldhaber, Samuel Z.
AU - Hassoun, Hani
AU - Hendrie, Paul
AU - Holmstrom, Bjorn
AU - Kuderer, Nicole
AU - Lee, Jason T.
AU - Millenson, Michael M.
AU - Neff, Anne T.
AU - Ortel, Thomas L.
AU - Siddiqi, Tanya
AU - Smith, Judy L.
AU - Yee, Gary C.
AU - Zakarija, Anaadriana
AU - McMillian, Nicole
AU - Naganuma, Maoko
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2013/11/1
Y1 - 2013/11/1
N2 - Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.
AB - Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.
UR - http://www.scopus.com/inward/record.url?scp=84891938450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891938450&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2013.0163
DO - 10.6004/jnccn.2013.0163
M3 - Article
C2 - 24225973
AN - SCOPUS:84891938450
SN - 1540-1405
VL - 11
SP - 1402
EP - 1429
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 11
ER -